Bristol Myers Squibb has tapped up Faro to use AI to improve the Big Pharma's clinical trial protocols. | Bristol Myers ...

The US approval is supported by Phase III SWOG 1826 data assessing Opdivo plus AVD.

Promotional materials for a handful of biologics have found their way into the FDA’s hot seat. | Promotional materials for a ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for approximately ...

While it is common to hear that drug developers are in the early stages of integrating artificial intelligence with their drug research, discovery, and development efforts, one Bristol Myers Squibb ...

The interest in the potential of antibody-drug conjugates (ADC) continues to grow among some of pharma’s biggest players. Bristol Myers Squibb (BMS) announced Thursday morning that it has entered into ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...